{"id":34014,"date":"2025-05-23T19:27:05","date_gmt":"2025-05-23T11:27:05","guid":{"rendered":"https:\/\/flcube.com\/?p=34014"},"modified":"2025-05-23T19:27:05","modified_gmt":"2025-05-23T11:27:05","slug":"remegen-plans-hong-kong-share-placement-to-fund-telitacicept-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34014","title":{"rendered":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion"},"content":{"rendered":"\n<p>China-based biopharma RemeGen Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.<\/p>\n\n\n\n<p><strong>Share Capital Structure<\/strong><br>As of the announcement date, RemeGen\u2019s total issued share capital comprises 544,608,243 shares. This includes 355,027,004 shares listed in mainland China and 189,581,239 shares listed in Hong Kong.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052200084_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025052200084_c.\"><\/object><a id=\"wp-block-file--media-0c3982d2-c853-4b2e-b3cd-1f1fc668b01b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052200084_c.pdf\">2025052200084_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025052200084_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0c3982d2-c853-4b2e-b3cd-1f1fc668b01b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34017,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1155,375],"class_list":["post-34014","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-9995","tag-remegen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34014\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion\" \/>\n<meta property=\"og:description\" content=\"China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34014\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-23T11:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion\",\"datePublished\":\"2025-05-23T11:27:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014\"},\"wordCount\":130,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2308.webp\",\"keywords\":[\"HKG: 9995\",\"RemeGen\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34014#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34014\",\"name\":\"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2308.webp\",\"datePublished\":\"2025-05-23T11:27:05+00:00\",\"description\":\"China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34014\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2308.webp\",\"width\":1080,\"height\":608,\"caption\":\"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34014#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34014","og_locale":"en_US","og_type":"article","og_title":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion","og_description":"China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.","og_url":"https:\/\/flcube.com\/?p=34014","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-23T11:27:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34014#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34014"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion","datePublished":"2025-05-23T11:27:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34014"},"wordCount":130,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34014#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp","keywords":["HKG: 9995","RemeGen"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34014#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34014","url":"https:\/\/flcube.com\/?p=34014","name":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34014#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34014#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp","datePublished":"2025-05-23T11:27:05+00:00","description":"China-based biopharma RemeGen Ltd (HKG: 9995) announced plans to place 10.2% of its issued shares listed in Hong Kong, with a par value of RMB 19 million. The offering is expected to generate gross proceeds of approximately HKD 806 million (USD 103 million). After deducting commissions and estimated expenses, the net proceeds are projected to reach HKD 796 million (USD 102 million). The company intends to use these funds to expand core indications for its flagship product, telitacicept (RC18), including myasthenia gravis and membranous nephropathy, as well as for general corporate purposes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34014#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34014"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34014#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp","width":1080,"height":608,"caption":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34014#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Plans Hong Kong Share Placement to Fund Telitacicept Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34014"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34014\/revisions"}],"predecessor-version":[{"id":34018,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34014\/revisions\/34018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34017"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}